Across TCGA pan-cancer cohorts, SCX Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SCX data layer compared with 23 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SCX Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SCX expression acts as an unfavorable survival marker.
LUSC are the cancer types where SCX Mutation most reproducibly stratifies survival.